Treatment of dyslipidemia in patients with type 2 diabetes

Abstract

Type 2 diabetes is associated with significant cardiovascular morbidity and mortality. Although low-density lipoprotein cholesterol levels may be normal in patients with type 2 diabetes, insulin resistance drives a number of changes in lipid metabolism and lipoprotein composition that render low-density lipoprotein cholesterol and other lipoproteins more pathogenic than species found in patients without type 2 diabetes. Dyslipidemia, which affects almost 50% of patients with type 2 diabetes, is a cardiovascular risk factor characterized by elevated triglyceride levels, low high-density lipoprotein cholesterol levels, and a preponderance of small, dense, low-density lipoprotein particles. Early, aggressive pharmacological management is advocated to reduce low-density lipoprotein cholesterol levels, regardless of baseline levels. A number of lipid-lowering agents, including statins, fibrates, niacin, and bile acid sequestrants, are available to target normalization of the entire lipid profile. Despite use of combination and high-dose lipid-lowering agents, many patients with type 2 diabetes do not achieve lipid targets. This review outlines the characteristics and prevalence of dyslipidemia in patients with type 2 diabetes and discusses strategies that may reduce the risk of cardiovascular disease in this population.

Micronutrient Vitamin Deficiencies and Cardiovascular Disease Risk: Advancing Current Understanding

“…It is posited that > 23 million people are expected to be affected by CVDs by 2030 [2,3]. Although the use of drug treatment for conventional cardiovascular risk factors has been very effective, recent studies suggest failure to reach the optimal levels of treatment only in some patient groups [4]. This scenario underscores the need for improved prevention and treatment strategies for CVDs as the key action for achieving the best results.…”

Features of Dyslipoproteinemia in Type 2 Diabetes Mellitus Patients With Prior Myocardial Infarction

“…Рiвень Апо В бiльш тiсно пов'язаний з ЦД та iнсулiнорезистентнiстю, нiж ЛПНЩ та ЛПВЩ, оскiльки мiститься в найбiльш атерогенних частках лiпопротеїнiв, а, вiд-повiдно, може краще прогнозувати серцево-судиннi подiї у таких хворих i є визнаним цiнним маркером кардiо-васкулярної захво-рюваностi [14]. Дослiдження останнiх рокiв показали, що у хворих на ЦД вiдбувається не лише кiлькiсне зменшення антиатероген-ного класу ЛПВЩ, але й може бути втраче-на їх протективна функцiя у зв'язку з пору-шенням структури складових бiлкiв на фонi прооксидантного та прозапального феноти-пу [15].…”

“…Визначення ж рiвня Апо А-1, як основного бiлка ЛПВЩ, за даними епiдемiологiчних та iнтервенцiйних дослiджень, на додаток до визначення Апо В, дозволяє бiльш точно прогнозувати серцево-судиннi ризики, нiж оцiнка звичайних лiпiдних показникiв. Так само, як i спiввiдношення Апо В / Апо А-1 за своєю точнiстю у прогнозуваннi ко-ронарного ризику перевершує можливо-стi iнших спiввiдношень холестеринових фракцiй [14].…”

The Effect of Polysaccharides Peptides Ganoderma Lucidum to Aortic Foam Cell Count and Lipid Profile in Type 2 Diabetic Model Rattus Norvegicus Strain Wistar

“…In the year 2035, this figure will be increased to 592 million. Indonesia is included in 10 countries in the world with the largest number of diabetics, with the number of patients as much as 8.5 million by 2013 (7 th rank) and is expected to be increased to 14.1 million of patients by 2035 (6 th rank).…”